Table 3.

Univariate analyses of OS and TTF in subgroup subsets. OS, overall survival; PS, performance status; LDH, lactate dehydrogenase, SVC, superior vena cava; wPTX, weekly paclitaxel; BV, bevacizumab; CI, confidence interval.

		OS					TTF
Factor		number of patients	number of events	Median (days)	95% CI	p	number of patients	number of events	Median (days)	95% CI	p
Performance status	0–1	31	24	416	294–712	0.003	31	30	145	74–181	0.9
	>2	13	12	155	69–287		13	12	125	40–182
Elevated LDH(>300U/L)	Yes	24	22	278	107–348	0.003	24	23	125	40–181	0.83
	No	20	14	666	275–943		20	19	149	65–197
Liver dysfunction	Yes	10	8	239	16–384	0.097	10	9	97	7–245	0.71
	No	34	28	364	261–666		34	33	147	86–181
Carcinomatous lymphangiomatosis or respiratory dysfunction	Yes	29	24	328	260–666	0.45	29	29	137	70–170	0.14
	No	15	12	323	93–712		15	13	125	25–245
SVC syndrome	Yes	2	1	279	279-∞	0.66	2	1	182	182-∞	0.11
	No	42	35	323	260–442		42	40	125	86–162
Bone marrow carcinomatosis	Yes	7	7	139	16–712	0.29	7	7	90	7–226	0.81
	No	37	29	348	275–637		37	35	137	89–177
Triple-negative breast caner	Yes	9	7	201	65-∞	0.23	9	8	125	28–203	0.95
	No	35	29	384	275–666		35	34	137	86–177
Dose reduction of wPTX	Yes	20	18	287	106–384	0.05	20	19	124	74–217	0.83
	No	24	18	481	260–891		24	23	141	60–181
Previous taxane therapy	Yes	23	19	384	261–666	0.8	23	22	137	90–177	0.75
	No	21	17	287	107–891		21	20	125	60–197
Line of wPTX + BV	1st-line	30	22	416	165–891	0.006	30	28	114	60–177	0.81
	2nd- or later	14	14	277	93–328		14	14	147	74–203